Login / Signup

Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study.

M LevyL MartinAnne-Claire BursztejnChristine ChiaveriniJ MiquelEmmanuel MahéAnnabel MaruaniF Boralevinull null
Published in: The British journal of dermatology (2019)
Our findings suggest the safety and efficacy of ivermectin for the treatment of scabies in infants and young children. What's already known about this topic? Scabies is a frequent condition in small children and infants, but the therapeutic options are limited. Ivermectin has been approved for the treatment of scabies in adults and children > 15 kg, but its use is off-label in infants and children weighing < 15 kg. Safety data on the use of ivermectin in children weighing < 15 kg are limited. What does this study add? Of 170 infants and children weighing < 15 kg who were treated for scabies with oral ivermectin, there were only seven reported mild adverse events and no serious ones. Our results show that ivermectin is effective in treating scabies in 85% of patients. Efficacy is higher when the received dose exceeds 200 μg kg-1 and when the delay between the two doses is < 10 days. Respond to this article.
Keyphrases
  • young adults
  • newly diagnosed
  • end stage renal disease
  • chronic kidney disease
  • prognostic factors
  • electronic health record
  • big data
  • patient reported